Related Experiment Video
Updated: Sep 26, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Immunotherapy and Checkpoint Inhibitors in Urologic Cancer
Aleksandra Walasek1, Dimitar V Zlatev1
1Department of Urology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Abstract:
Cancer immunotherapy has transformed urologic oncology by expanding the arsenal of available treatment options and improving outcomes. The number of patients eligible for immune-based cancer treatment continues to increase as indications for currently approved therapies expand with new agents being developed and studied. In this review the authors discuss the major recent clinical developments in immunotherapy for the treatment of urologic cancers.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

